Teleflex Inc header image

Teleflex Inc

TFX

Equity

ISIN US8793691069 / Valor 976212

New York Stock Exchange, Inc (2024-09-18)
USD 241.53+0.04%

Teleflex Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Teleflex Inc is a global company specializing in medical technologies aimed at enhancing the health and well-being of individuals. With a diverse portfolio of solutions in areas such as vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine, and respiratory care, Teleflex focuses on purpose-driven innovation to address unmet clinical needs and improve patient outcomes. With over 14,000 employees worldwide, the company is committed to making a difference in the healthcare industry through its innovative products and services.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (07.08.2024):

Revenue Growth

Teleflex Inc. reported revenues of $773.9 million for the fourth quarter of 2023, reflecting a 2.1% increase compared to the same period in the prior year. On a constant currency basis, the revenue growth was 0.7%. This growth was achieved despite having five fewer shipping days year-over-year.

EPS Performance

For the fourth quarter of 2023, Teleflex Inc. reported GAAP diluted earnings per share (EPS) from continuing operations of $0.66, a significant decrease from $1.65 in the prior year period. Adjusted diluted EPS from continuing operations was $3.38, compared to $3.52 in the same period last year.

Full Year Financials

Teleflex Inc. achieved full-year 2023 revenues of $2,974.5 million, marking a 6.6% increase year-over-year. On a constant currency basis, the revenue growth was 6.5%. The company reported GAAP diluted EPS from continuing operations of $7.56, slightly down from $7.67 in the previous year, while adjusted diluted EPS from continuing operations rose to $13.52 from $13.06.

2024 Guidance

For the full year 2024, Teleflex Inc. has provided a GAAP revenue growth guidance range of 3.60% to 4.60%. On a constant currency basis, the revenue growth guidance range is 3.75% to 4.75%. The company expects GAAP EPS from continuing operations to be between $5.69 and $6.09, and adjusted diluted EPS from continuing operations to range from $13.55 to $13.95.

Segment Performance

In the fourth quarter of 2023, Teleflex Inc.'s Americas segment reported revenues of $450.6 million, a 1.6% decrease year-over-year. The EMEA segment saw a 3.1% increase to $152.4 million, while the Asia segment experienced a significant 12.5% growth to $88.3 million. The OEM segment also performed well, with revenues increasing by 12.1% to $82.6 million.

Summarized from source with an LLMView Source

Key figures

14.3%1Y
-37.4%3Y
-29.1%5Y

Performance

28.5%1Y
31.0%3Y
33.3%5Y

Volatility

Market cap

11576 M

Market cap (USD)

Daily traded volume (Shares)

79,285

Daily traded volume (Shares)

1 day high/low

243.1 / 240.1

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Eurofins Scientific SE
Eurofins Scientific SE Eurofins Scientific SE Valor: 58317129
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.91%EUR 52.34
Dermapharm Holding SE
Dermapharm Holding SE Dermapharm Holding SE Valor: 40166352
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.43%EUR 35.10
Formycon AG
Formycon AG Formycon AG Valor: 12194189
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.10%EUR 49.35
Maternus-Kliniken AG
Maternus-Kliniken AG Maternus-Kliniken AG Valor: 335800
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.35%EUR 1.74
Vitrolife AB
Vitrolife AB Vitrolife AB Valor: 41707777
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.18%SEK 237.80
Elekta AB
Elekta AB Elekta AB Valor: 613625
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.88%SEK 68.70
BioArctic AB
BioArctic AB BioArctic AB Valor: 38514501
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.59%SEK 170.30
Camurus AB
Camurus AB Camurus AB Valor: 30510553
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.15%SEK 663.00
4basebio PLC
4basebio PLC 4basebio PLC Valor: 112829117
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%EUR 17.10
Cassava Sciences Inc
Cassava Sciences Inc Cassava Sciences Inc Valor: 46983284
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.13%USD 30.32